natgillin/translations-raw huggingface dataset:
Treatment with lutetium (177Lu) oxodotreotide is not recommended for patients with renal function between 30 and 50 mL/min therefore, the benefit risk for these patients will always need to be weighed carefully, which should include consideration of an increased risk for transient hyperkalemia in these patients.
Lu) oksodotreotidom ne priporoča, zato je treba pri teh bolnikih vedno pozorno oceniti razmerje med koristjo in tveganjem, kar mora vključevati upoštevanje povečanega tveganja za prehodno hiperkaliemijo pri teh bolnikih.
NAME OF THE MEDICINAL PRODUCT LysaKare 25 g/25 g solution for infusion
LysaKare 25 g/25 g raztopina za infundiranje
Very common
Zelo pogosti bruhanje
What LysaKare is
Kaj je zdravilo LysaKare
PHARMACEUTICAL FORM AND CONTENTS Solution for infusion
FARMACEVTSKA OBLIKA IN VSEBINA
NAME OF THE MEDICINAL PRODUCT LysaKare 25 g/25 g solution for infusion L-arginine hydrochloride/L-lysine hydrochloride
LysaKare 25 g/25 g raztopina za infundiranje L-argininijev klorid/ L-lizinijev klorid
What LysaKare is used for
Za kaj uporabljamo zdravilo LysaKare
Talk to your doctor before taking LysaKare if your kidneys, heart or liver are severely impaired or if you have a history of high blood levels of potassium (hyperkalaemia).
Če imate hudo okvaro ledvic, srca ali jeter, ali če ste v preteklosti imeli visoke vrednosti kalija v krvi (hiperkaliemijo), se pred uporabo zdravila LysaKare posvetujte z zdravnikom.
LysaKare is given as an infusion (drip) into a vein.
Zdravilo LysaKare se daje z infundiranjem v veno.
LysaKare is indicated for administration with PRRT with lutetium (177Lu) oxodotreotide therefore, it should only be administered by a health care provider experienced in the use of PRRT.
Lu) oksodotreotidom, torej ga lahko dajejo samo zdravstveni delavci z izkušnjami pri uporabi PRRT.
An increase of serum potassium levels may occur in patients receiving arginine and lysine.
Pri bolnikih ki prejemajo arginin in lizin se lahko zvišajo ravni kalija v serumu.
Patiens with hepatic impairment
Bolniki z jetrno okvaro
In case of severe symptomatic hyperkalaemia, discontinuation of LysaKare infusion should be considered, taking into consideration the risk-benefit of renal protection versus acute hyperkalaemia.
Pri tem je treba upoštevati razmerje med koristjo zaščite ledvic in tveganjem za akutno hiperkaliemijo.
Each infusion bag contains 25 g of L-arginine hydrochloride and 25 g of L-lysine hydrochloride.
Ena vreča za infundiranje vsebuje 25 g L-argininijevega klorida in 25 g L-lizinijevega klorida.
How to store LysaKare
Shranjevanje zdravila LysaKare
Clear, colourless solution, free from visible particles pH: 5.1 - 6.1
Bistra, brezbarvna raztopina brez vidnih delcev.
OTHER SPECIAL WARNING(S), IF NECESSARY Do not reconnect partially used bags.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
LysaKare should be administered as a 4-hour infusion (250 mL/hour) starting 30 minutes prior to administration of lutetium (177Lu) oxodotreotide to achieve optimal renal protection.
Zdravilo LysaKare je treba dajati s 4-urnim infundiranjem (250 ml/h), ki naj se začne 30 minut pred dajanjem lutecijevega (
The overwrap is a moisture barrier.
Zunanji ovoj je zaščita pred vlago.
LysaKare is used in adult patients to protect kidneys from unnecessary radiation during treatment with Lutathera (lutetium (177Lu) oxodotreotide), a radioactive medicine used to treat certain tumours.
Lu) oksodotreotidom), radioaktivnim zdravilom, ki se uporablja za zdravljenje določenih tumorjev.
Adverse drug reaction
Neželen učinek zdravila
Arginine and lysine undergo glomerular filtration and, via competition, interfere with renal resorption of lutetium (177Lu) oxodotreotide, reducing the radiation dose delivered to the kidney.
oksodotreotida v ledvicah ter tako zmanjšata dozo sevanja, ki se dovaja v ledvice.
LysaKare is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
Zdravilo LysaKare je indicirano za zmanjševanje izpostavitve ledvic sevanju med radionuklidno terapijo peptidnega receptorja (Peptide-Receptor Radionuclide Therapy - PRRT) z lutecijevim (
Renal impairment
Bolezni prebavil navzea
4.6 Fertility, pregnancy and lactation
• siljenje na bruhanje in bruhanje
The risk caused by radioactivity is thought to be very low.
Tveganje zaradi radioaktivnosti je predvidoma zelo majhno.
This summary was last updated in 04-2011.
Povzetek je bil nazadnje posodobljen 07-2010.
• dementia (loss of intellectual function).
• demence (izguba intelektualnih sposobnosti).
It must not be used in women who are pregnant.
Zdravilo se ne sme uporabljati pri nosečnicah.
The medicine is used to help in the diagnosis of the following conditions in adults (aged 18 years or over):
Zdravilo se uporablja za pomoč pri diagnosticiranju naslednjih bolezenskih stanj pri odraslih (starejših od 18 let):
In the larger of the two studies, the sensitivity of DaTSCAN was 97%.
V večji od obeh študij je bila občutljivost zdravila DaTSCAN 97-odstotna.
The European Commission granted a marketing authorisation valid throughout the European Union for DaTSCAN to GE Healthcare Limited on 27 July 2000.
Evropska komisija je dovoljenje za promet z zdravilom DaTSCAN, veljavno po vsej Evropski uniji, odobrila družbi GE Healthcare Limited dne 27. julija 2000.
In movement disorders, DaTSCAN has been studied in 254 adults in two main studies.
Pri motnjah gibanja so zdravilo DaTSCAN proučevali pri 254 odraslih v dveh glavnih študijah.
In the studies, images obtained in 45 healthy volunteers were compared with those obtained in 180 patients with Parkinson's disease or related diseases, and in 29 patients with essential tremor.
V študijah so slike, dobljene pri 45 zdravih prostovoljcih, primerjali s tistimi, dobljenimi pri 180 bolnikih s Parkinsonovo boleznijo ali povezanimi obolenji, ter pri 29 bolnikih z esencialnim tremorjem.
In all of the studies, the main measure of effectiveness was the accuracy of the diagnosis based on the images from the scan compared with the diagnosis made by a specialist doctor.
V vseh študijah je bilo glavno merilo učinkovitosti točnost diagnoze, ugotovljene na podlagi slik, v primerjavi z diagnozo, ki jo je ugotovil zdravnik specialist.
Other information about DaTSCAN:
Druge informacije o zdravilu DaTSCAN:
For more information about treatment with DaTSCAN, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom DaTSCAN preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
This document is a summary of the European public assessment report (EPAR) for DaTSCAN.
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo DaTSCAN.
This means that the disease identified by the doctor reading the images obtained using DaTSCAN matched the existing diagnosis of the patients in 97% of cases.
To pomeni, da je bolezen, kot jo je opredelil zdravnik, ki je tolmačil slike, pridobljene ob uporabi zdravila DaTSCAN, v 97 % ustrezala že obstoječi diagnozi bolnikov.
DaTSCAN is only handled and given by people who have experience in the safe handling of radioactive materials.
Z zdravilom DaTSCAN lahko rokujejo in ga dajejo le osebe, ki imajo izkušnje z varnim ravnanjem z radioaktivnimi snovmi.
If this happens, the amount of DaTSCAN attaching to these nerve cells is greatly reduced, which can be seen on the scan.
Če se to zgodi, je količina zdravila DaTSCAN, ki se veže na te živčne celice močno zmanjšana, kar se vidi na sliki.
In movement disorders, DaTSCAN was effective at detecting changes in the brain due to Parkinson's disease or related diseases.
Pri motnjah gibanja je bilo zdravilo DaTSCAN učinkovito pri zaznavanju sprememb v možganih, nastalih zaradi Parkinsonove bolezni ali povezanih bolezni.
A scan is taken three to six hours after the injection.
Tri do šest ur po injiciranju se opravi slikanje.
What benefit has DaTSCAN shown during the studies?
Kakšne koristi je zdravilo DaTSCAN izkazalo med študijami?
In dementia, the sensitivity of DaTSCAN in distinguishing dementia caused by Lewy bodies from other types of dementia ranged from 75 to 80%.
Pri demenci je bila občutljivost zdravila DaTSCAN pri razlikovanju demence, ki jo povzročajo Lewyjeva telesca, od drugih tipov demence 75- do 80-odstotna.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for DaTSCAN.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo DaTSCAN, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
In dementia, DaTSCAN has been studied in one main study involving 288 adults who had been diagnosed with dementia with Lewy bodies or Alzheimer's disease, or another form of dementia.
Pri demenci so zdravilo DaTSCAN proučevali v eni glavni študiji pri 288 odraslih bolnikih z diagnosticirano demenco z Lewyjevimi telesci ali Alzheimerjevo boleznijo, ali katero drugo obliko demence.
In patients with Parkinson's disease and related diseases, and in patients with dementia with Lewy bodies, there is typically a loss of nerve cells in the striatum containing dopamine.
Pri bolnikih s Parkinsonovo boleznijo in povezanimi obolenji ter bolnikih z demenco z Lewyjevimi telesci gre navadno za izgubo živčnih celic v striatumu, ki vsebujejo dopamin.
The CHMP decided that DaTSCAN's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila DaTSCAN večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
• movement disorders such as those seen in Parkinson's disease and other related diseases, where a loss of nerve cells leads to tremor (shaking), gait disturbance (problems with the way the patient walks) and stiffness of the muscles.
• težav pri gibanju, kakršne se opazijo pri Parkinsonovi bolezni in drugih sorodnih boleznih, kjer izguba živčnih celic privede do tremorja (tresenja), motenj pri hoji in otrplosti mišic.
DaTSCAN is given by slow injection lasting no less than 15 to 20 seconds into an arm vein.
Zdravilo DaTSCAN se daje v veno na roki s počasnim injiciranjem, ki traja najmanj 15 do 20 sekund.
What is the risk associated with DaTSCAN?
Kakšna tveganja so povezana z zdravilom DaTSCAN?
This can be seen using a special imaging technique called single-photon-emission computed tomography (SPECT), which detects the radioactive iodine-123.
To lahko opazujemo s posebno tehniko slikanja, imenovano enofotonska izsevna tomografija ali SPECT (single photon emission computed tomography), ki zazna radioaktivni jod-123.
DaTSCAN should only be used in patients who have been referred by a doctor with experience in the management of movement disorders or dementia.
Zdravilo DaTSCAN se lahko uporablja le pri bolnikih, ki jih je napotil zdravnik z izkušnjami v obravnavanju motenj gibanja ali demence.
DaTSCAN is used to help distinguish between a type of dementia known as ‘dementia with Lewy bodies' and Alzheimer's disease.
Zdravilo DaTSCAN se uporablja za razločevanje med vrsto demence, ki je znana kot „demenca z Lewyjevimi telesci“, in Alzheimerjevo boleznijo.
It is used to detect the loss of nerve cells in an area of the brain called the striatum, specifically the cells that release dopamine, a chemical messenger.
Uporablja se za ugotavljanje izgube živčnih celic v določenem predelu možganov, ki se imenuje striatum, zlasti celic, ki sproščajo kemijski prenašalec dopamin.
DaTSCAN is for diagnostic use only.
Zdravilo DaTSCAN je samo za diagnostične namene.
Ioflupane attaches specifically to structures on the surface of nerve cell endings in the striatum that are responsible for the transport of dopamine.
Ioflupan se veže na strukture na površini končičev živčnih celic v striatumu, ki so odgovorne za prenašanje dopamina.
When receiving DaTSCAN, patients must also take another medicine, such as iodine tablets, to prevent their thyroid gland from taking up the iodine contained in DaTSCAN.
Bolniki morajo med prejemanjem zdravila DaTSCAN jemati tudi drugo zdravilo (kot so tablete joda), ki njihovi ščitnici preprečuje absorpcijo joda iz zdravila DaTSCAN.
When DaTSCAN is injected, ioflupane (123I) is distributed through the body in the blood and accumulates in the striatum, where it attaches to the structures that transport dopamine.
Ko se zdravilo DaTSCAN injicira, se ioflupan (123I) prek krvi porazdeli po telesu in se zbere v striatumu, kjer se veže na strukture, ki prenašajo dopamin.
DaTSCAN should not be used in people who may be hypersensitive (allergic) to ioflupane or any of the other ingredients.
Zdravila DaTSCAN ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) ali katero koli drugo sestavino zdravila.
Why has DaTSCAN been approved?
Zakaj je bilo zdravilo DaTSCAN odobreno?
This enables diseases related to Parkinson's disease to be distinguished from essential tremor, and for Lewy body dementia to be distinguished from Alzheimer's disease.
To omogoča ločiti obolenja, povezana s Parkinsonovo boleznijo, od esencialnega tremorja, ter demenco z Lewyjevimi telesci od Alzheimerjeve bolezni.
DaTSCAN is a solution for injection that contains the active substance ioflupane (123I).
Zdravilo DaTSCAN je raztopina za injiciranje, ki vsebuje zdravilno učinkovino ioflupan (123I).
It contains a substance called ioflupane, which is labelled with 123I (iodine-123), a radioactive form of the chemical element iodine.
Vsebuje spojino imenovano ioflupan, ki je radioaktivno označena z 123I (jod-123), radioaktivno obliko kemičnega elementa joda.
For the full list of all side effects reported with DaTSCAN, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila DaTSCAN, glejte navodilo za uporabo.
This is taken one to four hours before DaTSCAN.
To zdravilo je treba vzeti eno do štiri ure pred in 12 do 24 ur po prejemu odmerka zdravila DaTSCAN.
The most common side effect with DaTSCAN (seen in between 1 and 10 patients in 100) is headache.
Najpogostejši neželeni učinki zdravila DaTSCAN (opaženi pri 1 do 10 bolnikih izmed 100) so povečan tek, glavobol, mravljinčenje in vrtoglavica.
Because tremor can also occur in ‘essential tremor' (tremor whose cause is unknown), DaTSCAN is used to help distinguish between essential tremor and diseases related to Parkinson's disease;
Ker se tremor lahko pojavi tudi pri „esencialnem tremorju“ (tremor, katerega vzrok ni znan), se zdravilo
The active substance in DaTSCAN, ioflupane (123I), is a radiopharmaceutical.
Zdravilna učinkovina zdravila DaTSCAN, ioflupan (123I), spada med radiofarmacevtske izdelke.
Resuscitation equipment should be available before DaTSCAN is given, in case the patient has an allergic reaction.
Ker lahko pri bolniku pride do alergijske reakcije, mora biti pred začetkom injiciranja zdravila DaTSCAN na voljo oprema za oživljanje.
How has DaTSCAN been studied?
Kako je bilo zdravilo DaTSCAN raziskano?
What is DaTSCAN used for?
Za kaj se zdravilo DaTSCAN uporablja?
How is DaTSCAN used?
Kako se zdravilo DaTSCAN uporablja?
What is DaTSCAN?
Kaj je zdravilo DaTSCAN?
How does DaTSCAN work?
Kako zdravilo DaTSCAN deluje?
The full EPAR for DaTSCAN can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo DaTSCAN je na voljo tukaj.
Packaging Content Package sizeWithdrawal period
Ovojnina Vsebina Velikost pakiranja
EU Number
EU številka Izmišljeno ime
(Invented) Name
Izmišljenoime Jakost
Pack size
Pot uporabe Ovojnina
If pain persists for more than 12 hours, the doctor should be consulted again.
Če bolečina ne izgine po več kot 12 urah, se je treba ponovno posvetovati z zdravnikom.
The vaccine was first studied in a number of laboratory studies in pigs.
Cepivo so najprej proučevali v več laboratorijskih študijah pri prašičih.
In the future, if the animals are exposed to the virus the immune system will be able to respond more quickly.
Ob ponovni izpostavitvi živali virusu v prihodnosti se bo imunski sistem tako hitreje odzval.
The vaccine does not contain any live PCV2 so that it cannot cause disease.
Cepivo ne vsebuje živega virusa PCV2, zato ta ne more povzročati bolezni.
The full EPAR for Porcilis PCV ID can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila Porcilis PCV ID je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Porcilis PCV ID's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Porcilis PCV ID večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Porcine circovirus vaccine (inactivated)
cepivo proti prašičjemu cirkovirusu (inaktivirano)
The vaccine contains small amounts of a protein from PCV2.
Cepivo vsebuje majhne količine beljakovine iz virusa PCV2.
The laboratory studies showed that the vaccine had its full effect against PCV2 by two weeks and that protection lasted 23 weeks after vaccination.
Laboratorijske študije so pokazale, da je cepivo svoj polni učinek proti OCV2 doseglo v dveh tednih in da je zaščita trajala 23 tednov po cepljenju.
This is a summary of the European public assessment report (EPAR) for Porcilis PCV ID.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Porcilis PCV ID.
The vaccine is given using a suitable needle-free device for injection into the skin.
Cepivo se daje z ustrezno napravo brez igle za injiciranje v kožo.
The European Commission granted a marketing authorisation valid throughout the EU for Porcilis PCV ID on 28 August 2015.
Evropska komisija je dovoljenje za promet z zdravilom Porcilis PCV ID, veljavno po vsej Evropski uniji, izdala 28. avgusta 2015.
When Porcilis PCV ID is given to pigs, the animals' immune system recognises the virus protein as ‘foreign' and reacts by building up an active immune response.
Ko prašiči prejmejo cepivo Porcilis PCV ID, imunski sistem živali prepozna beljakovino iz virusa kot „tujek“ ter se nanj odzove tako, da sproži aktivni imunski odziv.
The main measures of effectiveness were average daily weight gain in the finishing period (fattening pigs in the period prior to slaughter) and PCV2 viraemia (virus in the blood).
Glavni merili učinkovitosti sta bili povprečni dnevni prirastek telesne mase med zaključnim obdobjem (pitanjem prašičev v obdobju pred zakolom) in viremija virusa PCV2 (prisotnost virusa v krvi).
The most common side effect with Porcilis PCV ID (seen in more than 1 in 10 pigs) is a short-lived local reaction with hard non-painful swellings up to 2 cm in diameter which disappear within about five weeks of vaccination.
Najpogostejši neželeni učinek cepiva Porcilis PCV ID (opažen pri več kot 1 prašiču od 10) je kratkotrajna lokalna reakcija s trdimi nebolečimi oteklinami premera do 2 cm, ki izginejo v petih tednih po cepljenju.
PCV2 is recognised as the primary cause of post-weaning multisystemic wasting syndrome (PMWS), but is also associated with a number of other conditions collectively known as porcine circovirus disease in Europe (PCVD) e.g porcine respiratory disease complex (PRDC), enteritis, reproductive disorders.
PCV2 je znan kot primarni povzročitelj sindroma poodstavitvenega hiranja (PMWS), povezujemo pa ga tudi s številnimi drugimi boleznimi, ki jih v Evropi poznamo pod skupnim imenom prašičje cirkovirusne bolezni (PCVD), ki med drugim vključujejo prašičji respiratorni bolezenski kompleks (PRDC), enteritis in reproduktivne motnje.
The withdrawal period for meat from pigs treated with Porcilis PCV ID is ‘zero' days, which means that there is no mandatory waiting time.
Karenca za meso prašičev, zdravljenih s cepivom Porcilis PCV ID, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
The vaccine is used to reduce viraemia (presence of the virus in the blood), virus load in the lungs and lymphoid tissues and virus shedding.
Cepivo se uporablja za zmanjšanje viremije (prisotnosti virusa v krvi), virusnega bremena v pljučih in limfnih tkivih ter izločanja virusa.
Porcilis PCV ID has also been investigated in three field studies involving pig farms where PCV2 infection was present.
Zdravilo Porcilis PCV ID so raziskali tudi v treh terenskih študijah na prašičjih farmah, na katerih je bila prisotna okužba s PCV2.
In all three studies average daily weight gain in the finishing period was significantly higher in the pigs vaccinated with Porcilis PCV ID compared with the non-vaccinated pigs.
V vseh treh študijah je bil povprečni dnevni prirastek telesne mase med zaključnim obdobjem pri prašičih, cepljenih s cepivom Porcilis PCV ID, znatno večji kot pri necepljenih prašičih.
Porcilis PCV ID is an emulsion containing mineral oil.
Zdravilo Porcilis PCV ID je emulzija, ki vsebuje mineralno olje.
Similarly PCV2 viraemia was significantly lower in the vaccinated pigs compared with non-vaccinated pigs.
Podobno je bila tudi viremija virusa PCV2 pri cepljenih prašičkih znatno manjša kot pri necepljenih.
Porcilis PCV ID is available as an emulsion for injection and can only be obtained with a prescription.
Zdravilo Porcilis PCV ID je na voljo v obliki emulzije za injiciranje in se izdaja le na recept.
Porcilis PCV ID is a vaccine.
Zdravilo Porcilis PCV ID je cepivo.
Porcilis PCV ID contains the adjuvant light mineral oil and dl-α-tocopheryl acetate to enhance the immune response.
Zdravilo Porcilis PCV ID vsebuje tudi dodatka, lahko mineralno olje in dl-α-tokoferil acetat, ki povečata imunski odziv.
PCVDs are considered to have a severe impact on pig production.
Prašičje cirkovirusne bolezni imajo velik vpliv na prašičerejo.
The vaccine is also used to reduce loss of daily weight gain and mortality associated with PV2 infection.
Prav tako se uporablja za zmanjšanje izgube dnevnega prirasta telesne mase in umrljivosti, povezanih s to okužbo.
Porcilis PCV ID is a veterinary vaccine against porcine circovirus type 2 (PCV2) infection in pigs.
Zdravilo Porcilis PCV ID je cepivo za uporabo v veterinarski medicini proti okužbi s prašičjim cirkovirusom tipa 2 (PCV2) pri prašičih.
What are the risks associated with Porcilis PCV ID?
Kakšna tveganja so povezana z zdravilom Porcilis PCV ID?
What is Porcilis PCV ID and what is it used for?
Kaj je zdravilo Porcilis PCV ID in za kaj se uporablja?
For practical information about using Porcilis PCV ID, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za praktične informacije o uporabi zdravila Porcilis PCV ID naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For more information about treatment with Porcilis PCV ID, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za več informacij o zdravljenju z zdravilom Porcilis PCV ID naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
What benefits of Porcilis PCV ID have been shown in studies?
Kakšne koristi je zdravilo Porcilis PCV ID izkazalo v študijah?
Other information about Porcilis PCV ID
Druge informacije o zdravilu Porcilis PCV ID
Safety information has been included in the summary of product characteristics and the package leaflet for Porcilis PCV ID, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
V povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.